Tennis elbow, golfer's elbow, and chronic elbow tendinopathy — why cortisone shots keep failing and what regenerative medicine offers instead.
The Problem
When a Handshake Becomes a Challenge
It starts small. A twinge when you lift the kettle. A sharp jab when you turn a doorknob. Before long, opening a jar feels impossible, and you find yourself apologizing for a weak handshake at every business meeting.
Elbow tendinopathy — whether it strikes the outside (tennis elbow) or inside (golfer's elbow) — is uniquely devastating because it attacks the movements we take completely for granted. Gripping, twisting, lifting. The very foundation of hand function.
For the executive who can't hold a pen through a board meeting, the golfer whose swing sends lightning bolts through their forearm, or the grandparent who can't pick up their grandchild — the frustration goes beyond pain. It's the loss of capability.
The Cortisone Trap
Most patients follow a predictable path: physiotherapy, then anti-inflammatories, then cortisone injections. The cortisone feels miraculous — for about six weeks. Then the pain returns, often worse. Another injection. Another temporary fix. But here's what your doctor may not have told you:
Cortisone doesn't heal the tendon. It may actually damage it further.
A randomised controlled trial by Coombes et al. published in JAMA demonstrated that corticosteroid injection was associated with significantly worse outcomes at 12 months compared to physiotherapy, with high recurrence rates in the corticosteroid group<sup>2</sup>. The anti-inflammatory effect masks the pain while the tendon continues to degenerate.
Understanding Elbow Tendinopathy: Degeneration, Not Inflammation
The Tendinopathy Spectrum
Despite the historical name "tendinitis" (suggesting inflammation), researchers now understand that chronic elbow tendon pain is primarily a degenerative condition — tendinopathy, not tendinitis<sup>4</sup>. The tissue shows:
Types of Elbow Tendinopathy
Lateral Epicondylitis (Tennis Elbow)
- Affects the common extensor origin on the outer elbow
- Primarily involves the extensor carpi radialis brevis (ECRB) tendon
- Prevalence: 1-3% of the general population<sup>1</sup>
- Despite the name, only 5-10% of cases are related to tennis
Medial Epicondylitis (Golfer's Elbow)
- Affects the common flexor-pronator origin on the inner elbow
- Less common than lateral epicondylitis (ratio of approximately 1:3-1:7)
- Often associated with occupational overuse, throwing sports, and golf
Distal Biceps Tendinopathy
- Affects the biceps tendon insertion at the radial tuberosity
- Less common but increasingly recognized in active individuals
What the Research Says: Regenerative Medicine for Elbow Tendinopathy
MSC Therapy for Lateral Epicondylitis
A pivotal study by Lee et al. (2015) examined allogeneic adipose-derived mesenchymal stem cells (AD-MSCs) injected into the common extensor tendon origin in patients with chronic lateral epicondylitis refractory to conservative treatment. At 52-week follow-up<sup>3</sup>:
- VAS pain scores improved by approximately 78% from baseline (66.8 mm to 14.8 mm)
- Mayo Elbow Performance Score improved significantly from baseline (64.0 to 90.6)
- MRI demonstrated significant tendon defect repair with organized tissue regeneration
- No serious adverse events reported
PRP vs. Corticosteroids: The Evidence Shift
Mishra and Pavelko (2006) conducted one of the earliest comparative studies of PRP versus local anaesthetic (bupivacaine) injection for chronic elbow tendinosis. At final follow-up<sup>5</sup>:
- PRP group: 93% reduction in pain from baseline
- Control group (bupivacaine): only 16% improvement at 8 weeks
- The PRP group continued to improve over time while the control group showed minimal change
A larger randomised controlled trial by Peerbooms et al. (2010) confirmed these findings in 100 patients, demonstrating that PRP was significantly superior to corticosteroid injection at 1-year follow-up, with sustained improvement in DASH scores<sup>6</sup>.
Systematic Review Evidence
Cell Source Considerations
For elbow tendinopathy, the regenerative approach focuses on:
- Mesenchymal stem cells (MSCs) — differentiate into tenocytes and release trophic factors that promote tendon healing
- PRP (platelet-rich plasma) — concentrates growth factors (PDGF, TGF-β, VEGF) that stimulate the repair cascade
- Combination therapy — MSCs + PRP may offer synergistic benefits, with PRP creating a favourable microenvironment for MSC survival and differentiation
Academic Perspective
Established evidence: PRP is superior to corticosteroid injection for chronic lateral epicondylitis at 12+ months; corticosteroid injections worsen long-term outcomes.
Emerging evidence: MSC therapy shows promising results for tendon regeneration with structural repair visible on MRI, but larger randomised controlled trials are needed.
Limitations: Most MSC studies have small sample sizes (15-30 patients). Long-term data beyond 2 years is limited. Optimal cell source, dosing, and injection technique are still being refined.
Treatment Options Compared
Conservative Management
Injection Options
Surgical Options
Is Stem Cell Therapy Right for You?
Strong Candidates
- Chronic lateral or medial epicondylitis lasting 6+ months
- Failed conservative treatment (PT, bracing, NSAIDs)
- Failed or temporary relief from cortisone injections
- Active individuals seeking to maintain grip strength and function
- MRI showing tendon degeneration without complete tear
May Still Benefit
- Partial tendon tears (less than 50% thickness)
- Recurrent tendinopathy after previous surgical repair
- Early tendinopathy combined with comprehensive rehabilitation
- Occupational tendinopathy in workers unable to modify activities
Poor Candidates
- Complete tendon rupture requiring surgical repair
- Active infection at the injection site
- Unstable elbow joint with ligamentous laxity
- Tendinopathy caused by an underlying systemic condition (e.g., fluoroquinolone-induced)
Decision Framework
What to Expect: The Treatment Journey
Our 7-Day Protocol
Phase 1: Assessment & Preparation (Day 1-2)
- Comprehensive elbow evaluation with high-resolution ultrasound and MRI review
- Grip strength testing and functional assessment
- Medical history review and treatment planning
- Pre-treatment PRP preparation protocol
Phase 2: Treatment (Day 3-4)
- Ultrasound-guided MSC injection into the degenerative tendon zone
- Concurrent PRP delivery to enhance the healing microenvironment
- Optional combination with shockwave therapy to stimulate angiogenesis
- Post-injection protocol initiation
Phase 3: Recovery & Education (Day 5-7)
- Guided eccentric loading exercise instruction
- Activity modification guidelines and ergonomic assessment
- Follow-up imaging and progress review
- Comprehensive home exercise programme for continued recovery
Recovery Timeline
Premium Add-On Therapies
- IV NAD+ infusion — optimises cellular energy and supports tissue repair
- Exosome therapy — concentrated growth factor delivery for enhanced tendon healing
- Shockwave therapy (ESWT) — mechanotransduction stimulus to promote angiogenesis
- Massage and manual therapy — reduces compensatory muscle tension and improves blood flow
Frequently Asked Questions
Q: How is regenerative therapy different from cortisone injections?
A: Cortisone suppresses inflammation and pain temporarily but does nothing to heal the damaged tendon — and may worsen it over time<sup>2</sup>. Regenerative therapies (MSCs and PRP) deliver growth factors and progenitor cells that stimulate actual tissue repair. The goal is healing, not masking.
Q: Can stem cells actually repair a damaged tendon?
A: Research demonstrates that MSCs can differentiate into tenocyte-like cells and secrete trophic factors that promote tendon regeneration. MRI studies show structural improvement in tendon integrity following MSC injection, suggesting genuine tissue repair rather than just symptom relief<sup>3</sup>.
Q: How many injections will I need?
A: Most patients receive one treatment session. Some patients with severe degeneration may benefit from a second treatment at 6-12 months. Unlike cortisone, which may need repeated injections, regenerative therapy aims to address the underlying problem in one or two sessions.
Q: I've had multiple cortisone injections already. Can I still benefit?
A: Yes. Prior cortisone injections don't prevent regenerative therapy from working, though heavily damaged tendons may require a more intensive protocol. In fact, patients who have failed cortisone are often the best candidates for regenerative approaches.
Q: Is there any downtime after treatment?
A: You'll need to avoid heavy gripping and lifting for 2-4 weeks after treatment. Most patients can return to desk work within days and resume sports and heavy activities at 6-8 weeks. This is significantly less downtime than surgical options.
Q: What about De Quervain's tenosynovitis — does this apply?
A: While De Quervain's affects the wrist tendons rather than the elbow, the regenerative principles are similar. PRP has shown promising results for De Quervain's tenosynovitis in early studies. Our wrist and hand article covers this condition in detail.
Take the Next Step
Ready to find out if regenerative therapy could help your elbow?
- Take our 2-minute Joint Health Assessment to see if you're a candidate
- Book a Discovery Consultation with our regenerative medicine specialists
Our team will review your imaging, medical history, and specific condition to create a personalised treatment plan.